7th Mar 2016 12:43
LONDON (Alliance News) - Summit Therapeutics PLC Monday announced further positive data from its phase II trial of ridinilazole for the treatment of c.difficile infection, showing it preserves the gut microbiome in patients.
This supports previously reported results from the trial that showed ridinilazole to be "statistically superior" to vanomycin.
"These new results from the Phase 2 trial show ridinilazole preserves the patients' microbiome while simultaneously working to eradicate the C. difficile bacteria. The clinical data strongly suggest that ridinilazole treatment may be better able to protect against recurrent disease than the current standard of care," said Chief Executive Officer Glyn Edwards in a statement.
Shares in Summit were up 6.1% at 105.00 pence Monday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L